Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
NCT02867592Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in sarcoma, Wilms' tumor, Ewing sarcoma, rhabdomyosarcoma (RMS), soft tissue sarcoma (STS), sponsored by National Cancer Institute. Started May 2017; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
sarcomaWilms' tumorEwing sarcomarhabdomyosarcoma (RMS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02867592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867592.